Brought to you by 
GSK to sell Dr. Reddy's products in emerging markets
16 Jul 2009
Executive Summary
In the same month it finalized plans to form a flu vaccine joint venture with China's Shenzhen Neptunus, GlaxoSmithKline is forging yet another deal in the emerging market space. This time Dr. Reddy's Laboratories will partner its branded generic drugs and pipeline with the Big Pharma in Africa, the Middle East, Asia Pacific (excluding India), and Latin America.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
Deal Status
- Final
Deal Type
-
Alliance
- Co-Marketing
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK to sell Dr. Reddy's products in emerging markets
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice